ERS 2023: Advancements in Asthma Management Holistic and Personalized Insights
Under-Treated Asthma in Adults- A Common Problem
A study aimed to investigate the factors associated with under-treated asthma in a large adult asthma cohort. The study included 28,584 asthma patients aged > 18 years, registered in the Swedish National Airway Register between 2017 and 2019. The patients were categorized into treatment steps 1-3 and 4-5, with a focus on those in steps 1-3 with uncontrolled asthma, considering the potential for treatment escalation. The results revealed that among the 17318 patients in treatment steps 1-3, 9586 (55%) had under-treated asthma. Factors associated with under-treated asthma included female sex, older age, overweight or obesity, current smoking, and lower levels of education. Furthermore, under-treated asthma patients had a similar high risk of future exacerbations as in treatment steps 4-5. The study concluded that under-treated asthma in treatment steps 1-3 is a common issue and should be addressed, particularly for patients with risk factors such as female sex, smoking, higher BMI, and lower socioeconomic status. Proper evaluation of inhaler technique and treatment adherence is crucial, as these patients are at increased risk of future exacerbations.
Poster ID 5283, European Respiratory Society (ERS) International Congress 2023, Milan, Italy, 9-13 September 2023
Switching Patients to Maintenance and Reliever Therapy in The Emergency Department? - A Qualitative Study Exploring the Attitudes and Beliefs of Patients and Healthcare Professionals
This study evaluated the health beliefs and behaviors of adult patients who presented to the Emergency Department (ED) with asthma exacerbations and the attitudes of healthcare professionals (HCPs), including ED and primary care staff, towards asthma care, particularly the potential for switching long-term medications in the ED setting. This study was conducted in 2021/22, semi-structured face-to-face and online interviews were carried out with 19 patients and 19 HCPs who had received ethical approval. Patients expressed concerns about becoming dependent on steroids and relied on salbutamol inhalers. However, they demonstrated trust in HCPs to recommend appropriate treatments and were willing to try maintenance and reliever therapy. On the other hand, HCPs recognized the ED as an opportunity to optimize asthma control but had concerns about capacity-related tensions. Overall, both patients and HCPs expressed a willingness to explore new inhaler options in the ED to enhance asthma control. However, they highlighted the need for support during this transition, including access to informative resources for patients and clear guidelines for HCPs. These findings suggest the potential for improving long-term asthma management during ED visits.
Poster ID 5284, European Respiratory Society (ERS) International Congress 2023, Milan, Italy, 9-13 September 2023
Albuterol–Budesonide Asthma Rescue Inhaler: Patterns of As-Needed Use
This study, conducted in response to the FDA approval of albuterol-budesonide 180/160 µg inhaler for as-needed asthma treatment, aimed to assess its effectiveness and safety in patients aged 21-88 years. The research analyzed data from the MANDALA study, a Phase 3 randomized, double-blind, multicenter trial involving patients with moderate-to-severe asthma on corticosteroid-containing maintenance therapy who had experienced severe exacerbations in the past year. The results indicated that as-needed albuterol-budesonide 180/160 µg reduced the risk of severe exacerbations by 28% compared to albuterol alone. Both groups showed similar patterns of inhaler use, with most patients using 0-≤2 inhalations on 50-54% of days and ≤4 inhalations on 85% of days. The study found that only a small percentage of patients (less than 5%) used an average of ≥6 inhalations/day of albuterol-budesonide, and this subgroup did not experience a clinically significant increase in adverse events compared to those using albuterol alone. Overall, the study supported the effectiveness and safety of as-needed albuterol-budesonide 180/160 µg inhaler in reducing severe exacerbation risk in asthma patients aged 21-88 years, with no notable increase in adverse events even in higher usage scenarios.
Poster ID 5292, European Respiratory Society (ERS) International Congress 2023, Milan, Italy, 9-13 September 2023

